← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Elisabeth Björk
Styrelseledamot
Profile key: se|elisabeth björk
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 2
- Purchases · 24M
- 3
- Average purchase
- SEK 172,000
- Gross purchase value
- SEK 516,000
- Last purchase
- 2026-09-22
- Completed 20D events
- 2.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Vicore Pharma Holding AB
Companies: Camurus AB | VICORE PHARMA HOLDING AB (publ) | Vicore Pharma Holding AB
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -1.1% | -1.0% | -3.2% |
| 20D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +3.6% | +3.6% | -4.7% |
| 60D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +19.7% | +19.7% | +3.5% |
| 120D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +17.3% | +17.3% | +17.0% |
Research patterns
- First purchase in 12M
- 2/2
- Large purchase ≥ €100k
- 0/1
- Cluster buying · 15D
- 0/3
- Buying the dip · ≥20% below prior 52W high
- 3/3
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.